Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Sept. 5, 2025—Agilent Technologies has introduced three models to its Dako Omnis family of instruments—the Omnis 110, 165, and 165 Duo—designed to provide laboratories with the flexibility to tailor staining solutions according to volume, workflow, and diagnostic requirements.
Sept. 4, 2025—MeMed announced that several oral presentations at the American College of Emergency Physicians Scientific Assembly 2025, Sept. 7–10 in Salt Lake City, will showcase clinical evidence supporting the utility of MeMed BV, an FDA-cleared test that distinguishes between bacterial and viral infections based on the body’s immune response.
Sept. 2, 2025—Qiagen has launched QIAstat‑Dx Rise, a version of the QIAstat-Dx automated syndromic testing system.
Aug. 28, 20205—Tempus AI is acquiring Paige for $81.25 million.
Aug. 27, 2025—Randox Laboratories plans to expand its facility in Jefferson County, W. Va., from a 48-person sales and distribution operation to a full-scale production laboratory.
Aug. 26, 2025—SehaMed Global (Bristol, England) announced a strategic distribution agreement with New Day Diagnostics, of Knoxville, Tenn., to bring ColoHealth, an FDA-approved blood test for the early detection of colorectal cancer, to patients in Saudi Arabia, the United Arab Emirates, and other countries in the Middle East.
Aug. 25, 2025—Ifinatamab deruxtecan (I-DXd) has been granted breakthrough therapy designation by the FDA for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.
Aug. 18, 2025—The FDA has granted breakthrough device designation to Artera’s ArteraAI Prostate, an AI precision medicine tool intended to assist clinicians with risk-based decisions for patients with localized prostate cancer.
Aug. 15, 2025—QuidelOrtho Corp. has launched a certified analyzer program designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States.
Aug. 14, 2025—Bio-Rad Laboratories has launched its Unity Next Peer QC data management software throughout the Asia-Pacific region.
